AMRI Secures Seven-Year NIH Contract for APIs and Drug Product

Under the contract, AMRI will focus on the development and manufacture of APIs and drug product for Phase I clinical studies.
Jun 06, 2018
By Pharmaceutical Technology Editors

AMRI, a global contract research, development, and manufacturing organization, has secured a seven-year contract from the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to develop and manufacture active pharmaceutical ingredients (APIs) and drug product for Phase I clinical studies, the company announced on June 6, 2018. The company will conduct the bulk of this work its Albany, NY, facilities.

“Our new contract with the NIH not only enhances AMRI’s ability to positively impact the health of the general public, but it also serves as a testament of our work, giving prospective customers confidence in our aptitude to solve complex scientific challenges,” noted Christopher Conway, senior vice president of discovery, development, and analytical services and fine chemicals, at AMRI, in a company press release. “We are excited for the opportunity to further support this well-respected government agency aimed at advancing their researchers’ programs.”

In addition to this contract, AMRI is also contracted to provide services to other NIH-funded researchers, including being selected as a dedicated chemical biology consortium (CBC) center for the National Cancer Institute experimental therapeutics program and programs for the National Center for Advancing Translational Sciences and the Blueprint Neurotherapeutics Network.

Source: AMRI

native1_300x100
lorem ipsum